[go: up one dir, main page]

MX2024014238A - Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer - Google Patents

Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer

Info

Publication number
MX2024014238A
MX2024014238A MX2024014238A MX2024014238A MX2024014238A MX 2024014238 A MX2024014238 A MX 2024014238A MX 2024014238 A MX2024014238 A MX 2024014238A MX 2024014238 A MX2024014238 A MX 2024014238A MX 2024014238 A MX2024014238 A MX 2024014238A
Authority
MX
Mexico
Prior art keywords
methods
immunogenic compositions
tert
treatment
same
Prior art date
Application number
MX2024014238A
Other languages
English (en)
Inventor
David Weiner
Jian Yan
Original Assignee
Univ Pennsylvania
Wistar Inst
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Wistar Inst, Inovio Pharmaceuticals Inc filed Critical Univ Pennsylvania
Publication of MX2024014238A publication Critical patent/MX2024014238A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen composiciones que comprenden antígenos TERT de consenso optimizados y métodos para tratar el cáncer y, en particular, composiciones inmunogénicas que tratan y proporcionan protección contra el tumor.
MX2024014238A 2016-09-30 2019-03-29 Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer MX2024014238A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402695P 2016-09-30 2016-09-30
US201762468124P 2017-03-07 2017-03-07
PCT/US2017/054519 WO2018064588A2 (en) 2016-09-30 2017-09-29 Tert immunogenic compositions and methods of treatment using the same

Publications (1)

Publication Number Publication Date
MX2024014238A true MX2024014238A (es) 2024-12-06

Family

ID=61760146

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2019003722A MX2019003722A (es) 2016-09-30 2017-09-29 Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2024014237A MX2024014237A (es) 2016-09-30 2019-03-29 Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer
MX2024014239A MX2024014239A (es) 2016-09-30 2019-03-29 Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer
MX2024014238A MX2024014238A (es) 2016-09-30 2019-03-29 Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2019003722A MX2019003722A (es) 2016-09-30 2017-09-29 Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2024014237A MX2024014237A (es) 2016-09-30 2019-03-29 Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer
MX2024014239A MX2024014239A (es) 2016-09-30 2019-03-29 Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer

Country Status (9)

Country Link
US (2) US11464841B2 (es)
EP (1) EP3518955A4 (es)
JP (3) JP7781511B2 (es)
KR (3) KR20230167445A (es)
CN (3) CN119326876A (es)
AU (2) AU2017336088B2 (es)
CA (1) CA3038889A1 (es)
MX (4) MX2019003722A (es)
WO (1) WO2018064588A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102364214B1 (ko) * 2010-11-12 2022-02-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
US11865166B2 (en) * 2016-08-29 2024-01-09 The Trustees Of The University Of Pennsylvania Nucleic acid encoding optimized immunogenic peptide that targets follicle stimulating hormone receptor
WO2018053070A1 (en) * 2016-09-14 2018-03-22 Intellia Therapeutics, Inc. Improved methods for analyzing edited dna
EP3515466A4 (en) * 2016-09-21 2020-05-27 The Trustees of The University of Pennsylvania OPTIMIZED SYNTHETIC INMUNOGENOUS CONSENSUS COMPOSITIONS AGAINST FIBROBLAST ACTIVATION PROTEIN
CA3122259A1 (en) * 2018-12-05 2020-06-11 Linearx, Inc. Amplicon expression vector vaccines
WO2020131656A1 (en) * 2018-12-17 2020-06-25 Immune Design Corp. Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer
WO2021051065A1 (en) * 2019-09-12 2021-03-18 Inovio Pharmaceuticals, Inc. Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same
US20210128710A1 (en) * 2019-11-04 2021-05-06 Inovio Pharmaceuticals, Inc. Combination therapy to treat brain cancer
US20250152687A1 (en) * 2020-07-29 2025-05-15 Evvivax S.R.L. Consensus sequence of the antigen telomerase and the use thereof in preventive and therapeutic vaccination
AU2022328341A1 (en) * 2021-08-13 2024-04-04 Inovio Pharmaceuticals, Inc. Combination therapy to treat brain cancer
KR20250080087A (ko) 2023-11-28 2025-06-05 주식회사 엘지에너지솔루션 파우치 성형 장치
CN118064503B (zh) * 2024-03-08 2024-08-02 上海联衡生物科技有限公司 一种基于端粒酶基因的双基因表达载体及其制备和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3456099A (en) * 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
AU1331100A (en) * 1998-10-29 2000-05-22 Dana-Farber Cancer Institute Cancer immunotheraphy and diagnosis using universal tumor associated antigens, including htert
JP2004527449A (ja) * 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
EP1257284A4 (en) * 2000-02-15 2005-12-21 Univ California UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE
EP1572090A4 (en) 2002-06-27 2006-11-15 Geron Corp CANCER VACCINE WITH CROSS-SPEED EPITOPES OF THE TELOMERASE REVERSE TRANSCRIPTASE
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
CA3184778A1 (en) * 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
ATE534661T1 (de) * 2006-10-12 2011-12-15 Angeletti P Ist Richerche Bio Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon
WO2013067652A1 (en) * 2011-11-10 2013-05-16 Beijing Advaccine Biotechnology Co., Ltd. Facilitator-dna combination vaccine
CA2898126A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
EP2871235A1 (en) * 2013-11-07 2015-05-13 Centre National de la Recherche Scientifique (CNRS) New methods to produce active hTERT
EP3515466A4 (en) * 2016-09-21 2020-05-27 The Trustees of The University of Pennsylvania OPTIMIZED SYNTHETIC INMUNOGENOUS CONSENSUS COMPOSITIONS AGAINST FIBROBLAST ACTIVATION PROTEIN
WO2018204760A1 (en) * 2017-05-05 2018-11-08 David Weiner Ctla4 antibodies and vaccine combinations and use of same for immunotherapy

Also Published As

Publication number Publication date
JP2019534875A (ja) 2019-12-05
US20200030426A1 (en) 2020-01-30
CA3038889A1 (en) 2018-04-05
JP2025113243A (ja) 2025-08-01
CN119326876A (zh) 2025-01-21
KR102375328B1 (ko) 2022-03-21
EP3518955A4 (en) 2020-10-07
CN110573173A (zh) 2019-12-13
AU2023237174A1 (en) 2023-10-26
KR20220024974A (ko) 2022-03-03
AU2017336088B2 (en) 2023-07-06
WO2018064588A2 (en) 2018-04-05
US20230115179A1 (en) 2023-04-13
CN110573173B (zh) 2024-11-08
JP7781511B2 (ja) 2025-12-08
US11464841B2 (en) 2022-10-11
WO2018064588A3 (en) 2018-05-03
MX2024014239A (es) 2024-12-06
KR20230167445A (ko) 2023-12-08
AU2017336088A1 (en) 2019-05-02
MX2024014237A (es) 2024-12-06
KR20190120743A (ko) 2019-10-24
MX2019003722A (es) 2019-09-26
JP2022179497A (ja) 2022-12-02
CN119345342A (zh) 2025-01-24
EP3518955A2 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
MX2024014238A (es) Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer
PH12020551923A1 (en) Methods and compositions for treating cancer
IL287643A (en) Preparations and methods for treating cancer using tet2 transgenic t cell therapy
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
ZA201905222B (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
GB2557123A (en) Modified cells and methods of therapy
MY194586A (en) Anti-garp antibody
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
MD20170073A2 (ro) Terapii combinate pentru tratarea cancerelor
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
HK1248588A1 (zh) 用於癌症治疗中的天花疫苗
MX2019009753A (es) Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos.
MX2018002344A (es) Metodo para tratar el cancer.
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
GEAP202114756A (en) Combination therapy for the treatment of cancer
EP4640237A3 (en) Macrophage-based therapy for use in the treatment of acute liver injury
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.